8-K: AbbVie Reports Strong 2025 Sales, Guides Robust 2026 EPS

AbbVie announced record net sales for 2025, driven by its diversified growth platform, and provided an optimistic adjusted diluted EPS guidance for 2026.

Summary

• Full-Year 2025 GAAP Diluted EPS was $2.36, a decrease of 1.3% compared to the prior year.
• Full-Year 2025 Adjusted Diluted EPS was $10.00, a decrease of 1.2%, which includes an unfavorable impact of $2.76 per share related to acquired IPR&D and milestones expense.
• Full-Year 2025 Net Revenues reached $61.160 billion, an increase of 8.6% on a reported basis and 8.5% on an operational basis.
• Fourth-Quarter 2025 GAAP Diluted EPS was $1.02, while Adjusted Diluted EPS was $2.71, including an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense.
• Fourth-Quarter 2025 Net Revenues were $16.618 billion, an increase of 10.0% on a reported basis and 9.5% on an operational basis.
• The Immunology portfolio generated $30.406 billion in global net revenues for the full year, an increase of 14.0% reported, with Skyrizi at $17.562 billion and Rinvoq at $8.304 billion.
• Global Humira net revenues for the full year were $4.540 billion, a decrease of 49.5% reported.
• The Neuroscience portfolio achieved $10.767 billion in global net revenues for the full year, an increase of 19.6% reported, including Vraylar at $3.621 billion and Botox Therapeutic at $3.769 billion.
• The Oncology portfolio's global net revenues for the full year were $6.655 billion, an increase of 1.5% reported, with Imbruvica at $2.869 billion and Venclexta at $2.792 billion.
• The Aesthetics portfolio's global net revenues for the full year were $4.860 billion, a decrease of 6.1% reported, with Botox Cosmetic at $2.602 billion and Juvederm at $993 million.
• AbbVie provided 2026 Adjusted Diluted EPS guidance in the range of $14.37 to $14.57, excluding any impact from acquired IPR&D and milestones expense.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating successful diversification post-Humira LOE with robust growth in key therapeutic areas and a positive outlook for 2026, despite the EPS impact from IPR&D expenses.

Positives

• Achieved record net sales in 2025, demonstrating the strength of its diversified growth platform just two years after the U.S. Humira loss of exclusivity.
• Immunology portfolio showed robust growth, with full-year global net revenues increasing 14.0% to $30.406 billion, driven by Skyrizi (up 49.9% to $17.562 billion) and Rinvoq (up 39.1% to $8.304 billion).
• Neuroscience portfolio delivered strong performance, with full-year global net revenues increasing 19.6% to $10.767 billion.
• Received FDA approval for Epkinly in combination with rituximab and lenalidomide (R2) for relapsed or refractory follicular lymphoma, marking its third indication and the first FDA approval for a bispecific combination therapy in lymphoma.
• Submitted applications to the U.S. FDA and European Medicines Agency (EMA) for Rinvoq for non-segmental vitiligo, potentially making it the first systemic treatment for this autoimmune disease.
• Submitted an application to the EMA for expanded use of Aquipta for the acute treatment of migraine, supported by positive Phase 3 study data.
• Entered an exclusive licensing agreement with RemeGen for RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody, strengthening the oncology portfolio.
• Acquired a device manufacturing facility and associated intellectual property from West Pharmaceutical Services to support production of current and next-generation immunology and neuroscience medicines.
• Committed $100 billion in U.S. R&D and capital investments, including manufacturing, over the next decade as part of a voluntary agreement with the Trump administration, providing exemption from tariffs and future pricing mandates.

Negatives

• Full-Year 2025 GAAP Diluted EPS decreased by 1.3% to $2.36.
• Full-Year 2025 Adjusted Diluted EPS decreased by 1.2% to $10.00, significantly impacted by $2.76 per share in acquired IPR&D and milestones expense.
• Global Humira net revenues decreased substantially by 49.5% for the full year 2025 due to U.S. loss of exclusivity.
• Aesthetics portfolio global net revenues decreased by 6.1% for the full year 2025.
• Juvederm net revenues decreased by 15.6% for the full year 2025 and 10.7% for the fourth quarter 2025.
• Oncology portfolio showed modest growth of 1.5% for the full year 2025 and a decrease of 1.5% for the fourth quarter 2025.
• Global Imbruvica net revenues decreased by 14.3% for the full year 2025 and 20.8% for the fourth quarter 2025.
• The Phase 3 EPCORE DLBCL-1 trial for Epkinly in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) did not demonstrate a statistically significant improvement in overall survival (OS), despite improvements in progression-free survival and complete response rates.

Risks

• Challenges to intellectual property.
• Competition from other products.
• Difficulties inherent in the research and development process.
• Adverse litigation or government action.
• Changes to laws and regulations applicable to the industry.
• Impact of global macroeconomic factors, such as economic downturns or uncertainty.
• International conflict, trade disputes and tariffs.
• Other uncertainties and risks associated with global business operations.

Future Outlook

AbbVie is providing adjusted diluted EPS guidance for the full-year 2026 in the range of $14.37 to $14.57. This guidance excludes any impact from acquired IPR&D and milestones expense, as these cannot be reliably forecasted. Management anticipates another year of robust growth in 2026, driven by strong fundamentals and strategic investments in innovation, positioning the company for long-term success.

Management Comments

• "2025 was another outstanding year for AbbVie. We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform."
• "We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments."
• "Based on our strong fundamentals, we expect another year of robust growth in 2026. This momentum combined with our investments in innovation position AbbVie for long-term success."

Industry Context

StockSavvy.ai notes that AbbVie's ability to deliver record net sales in 2025, despite the significant U.S. Humira loss of exclusivity, highlights a successful diversification strategy. The strong performance of Skyrizi and Rinvoq in immunology, alongside growth in neuroscience, demonstrates the company's effective pipeline development and commercial execution in key therapeutic areas. The strategic investments in R&D and acquisitions, such as the RemeGen licensing agreement and the West Pharmaceutical Services facility, are crucial for sustaining long-term growth and competitiveness in the evolving biopharmaceutical landscape. The agreement with the Trump administration regarding drug pricing and R&D investment also positions AbbVie favorably in the U.S. market.

Comparison to Industry Standards

• StockSavvy.ai observes that AbbVie's successful pivot post-Humira exclusivity loss, with Skyrizi and Rinvoq driving substantial immunology growth, sets a high benchmark for pharmaceutical companies facing patent cliffs. For instance, companies like Bristol Myers Squibb (BMS) and Merck (MRK) are also navigating patent expirations for key drugs, and AbbVie's strategy provides a strong case study in pipeline diversification and new product ramp-up.
• The 49.9% growth in Skyrizi and 39.1% growth in Rinvoq for FY25 are exceptionally strong for established products, outperforming many industry peers' growth rates for their blockbuster drugs.
• The commitment of $100 billion in U.S. R&D and capital investments over the next decade is a substantial long-term investment, comparable to the scale of R&D spending seen from top-tier pharmaceutical innovators like Pfizer (PFE) or Johnson & Johnson (JNJ), signaling a strong commitment to innovation and domestic manufacturing.
• The approval of Epkinly for follicular lymphoma, a bispecific combination therapy, positions AbbVie at the forefront of oncology innovation, competing with companies like Roche (RHHBY) and Regeneron (REGN) in the bispecific antibody space.

Legal Proceedings

• The reconciliation tables for 2024 included charges related to actual and potential settlements of litigation, and the forward-looking statements section mentions risks from adverse litigation or government action.

Stakeholder Impact

• Shareholders: Positive impact from record net sales, strong growth in key products, and optimistic 2026 EPS guidance. Potential concern from the decrease in 2025 EPS, though explained by IPR&D expenses.
• Employees: Positive implications from strategic investments and facility acquisition, suggesting continued growth and stability.
• Customers/Patients: Benefit from new drug approvals (Epkinly) and submissions for new indications (Rinvoq for vitiligo, Aquipta for migraine), expanding treatment options.
• Suppliers: Potential for increased business due to expanded manufacturing capabilities and R&D investments.
• Creditors: Strong financial performance and diversified revenue streams enhance creditworthiness.

Next Steps

• AbbVie will engage global regulatory authorities to discuss next steps for Epkinly in R/R DLBCL, following the Phase 3 EPCORE DLBCL-1 trial results.
• AbbVie will host an investor conference call on February 4, 2026, at 8:00 a.m. Central Time to discuss fourth-quarter performance.
• Continued development, manufacturing, and commercialization of RC148 under the licensing agreement with RemeGen.
• Integration and utilization of the acquired device manufacturing facility from West Pharmaceutical Services.
• Ongoing R&D and capital investments in the U.S. over the next decade as part of the agreement with the Trump administration.

Key Dates

Recommendation

AbbVie has demonstrated exceptional resilience and strategic execution in navigating the Humira patent cliff, successfully transitioning to a diversified growth platform led by Skyrizi and Rinvoq. The record net sales in 2025, robust growth in immunology and neuroscience, and a strong 2026 adjusted EPS guidance of $14.37 to $14.57 underscore the company's fundamental strength and future potential. While 2025 EPS saw a slight decline, it was primarily due to significant, non-recurring IPR&D expenses, which are common in the industry and do not reflect underlying operational weakness. The strategic pipeline advancements, new drug approvals, and substantial long-term R&D commitments further solidify AbbVie's position as a leading biopharmaceutical innovator. The company's ability to deliver growth in a challenging environment makes it a compelling "strong buy" for long-term investors.

Keywords

AbbVie, ABBV, financial results, earnings, 2025 results, 2026 guidance, pharmaceuticals, biopharmaceutical, immunology, neuroscience, oncology, aesthetics, Skyrizi, Rinvoq, Humira, Vraylar, Botox Therapeutic, Epkinly, pipeline, R&D, drug development, patent cliff